BioPharmSignal logoBioPharmSignal

Biotech News

PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀’s New Drug Application

PolyPid (PYPD)PolyPid2026-06-25 13:46 ESTFDA / regulatory

FDA Grants $4. 3 Million Small Business Waiver, Enabling Focus on Commercialization Preparations Company On Track to Initiate NDA Submission by the End of th is Month PETACH TIKVA, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative

Open original release

Related news

PYPDPolyPid2026-06-25 13:46 EST

PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀

PYPDPolyPid2026-06-25 13:46 EST

PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference

PYPDPolyPid2026-06-25 13:46 EST

PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results

PYPDPolyPid2026-06-25 13:46 EST

PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission

PYPDPolyPid2026-06-25 13:46 EST

PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

PYPDPolyPid2026-06-25 13:46 EST

PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026

PYPDPolyPid2026-06-25 13:46 EST

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

PYPDPolyPid2026-06-25 13:46 EST

PolyPid Announces Participation in Upcoming Investor Conferences

PYPDPolyPid2026-06-25 13:46 EST

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

PYPDPolyPid2026-06-25 13:46 EST

PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026

View all latest news

PolyPid

PolyPid is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

PYPDPolyPid2026-06-26 08:20 EST

PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀

PYPDPolyPid2026-06-26 08:20 EST

PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference

PYPDPolyPid2026-06-26 08:20 EST

PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results

PYPDPolyPid2026-06-26 08:20 EST

PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission

PYPDPolyPid2026-06-26 08:20 EST

PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States